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Introduction
The gram- positive bacterium Streptococcus pyogenes (group 
A Streptococcus) is a human- specific pathogen responsible 
for mild throat and skin infections and for life- threatening 
conditions resulting in ~500,000 deaths annually (Carapetis 
et al. 2005). The most studied virulence factor of this 
pathogen is the polymorphic and surface- localized M 
protein, a dimeric coiled- coil molecule that inhibits phago-
cytosis and contributes to virulence also by other mecha-
nisms (Fischetti 1989; Waldemarsson et al. 2009). This 
fibrillar protein has an amino- terminal and wall- distal 
hypervariable region (HVR), which exhibits extreme 
sequence variability among strains but not within a strain, 
allowing the identification of ~200 M (or emm) types 
(Steer et al. 2009). The HVR has attracted much atten-
tion, because it is a target for type- specific protective 
antibodies (Abs), is used for typing and classification, 
commonly binds a host ligand, and is evaluated as a 
vaccine component (Fischetti 1989; Morfeldt et al. 2001; 
Persson et al. 2006; Dale et al. 2011; Gustafsson et al. 
2013; Sanderson- Smith et al. 2014).
We previously presented evidence that the HVR of an 
M protein elicits a much weaker antibody response than 
the remaining part of the protein, although the HVR is 
a key target for protective Abs (Lannergård et al. 2011). 
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Abstract
The M protein of Streptococcus pyogenes, a major bacterial virulence factor, has 
an amino- terminal hypervariable region (HVR) that is a target for type- specific 
protective antibodies. Intriguingly, the HVR elicits a weak antibody response, 
indicating that it escapes host immunity by two mechanisms, sequence variability 
and weak immunogenicity. However, the properties influencing the immunogenic-
ity of regions in an M protein remain poorly understood. Here, we studied the 
antibody response to different regions of the classical M1 and M5 proteins, in 
which not only the HVR but also the adjacent fibrinogen- binding B repeat region 
exhibits extensive sequence divergence. Analysis of antisera from S. pyogenes- 
infected patients, infected mice, and immunized mice showed that both the HVR 
and the B repeat region elicited weak antibody responses, while the conserved 
carboxy- terminal part was immunodominant. Thus, we identified a correlation 
between sequence variability and weak immunogenicity for M protein regions. 
A potential explanation for the weak immunogenicity was provided by the dem-
onstration that protease digestion selectively eliminated the HVR- B part from 
whole M protein- expressing bacteria. These data support a coherent model, in 
which the entire variable HVR- B part evades antibody attack, not only by se-
quence variability but also by weak immunogenicity resulting from protease 
attack.
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This property may seem paradoxical, but should be 
 advantageous to the bacterium, by allowing it to escape 
anti- HVR Abs by two mechanisms, which act at different 
stages of an infection. While sequence variability causes 
antigenic variation that favors the establishment of an 
infection, a weak Ab response will delay the appearance 
of protective immunity in an infected host, thereby pro-
longing the infection.
The intriguing finding that the HVR of an M protein 
is weakly immunogenic prompted us to perform the studies 
reported here, aimed at systematically analyzing the Ab 
response to different regions of an M protein and at study-
ing the molecular basis for weak immunogenicity. Studies 
of two different M proteins was deemed important, to 
ensure that any findings would not reflect properties unique 
to one protein. As in our previous study, we employed 
the M1 and M5 proteins, two classical M proteins that 
have been epidemiologically associated with life- threatening 
invasive infections and rheumatic fever, respectively, the 
most serious diseases caused by S. pyogenes (Carapetis et al. 
2005). These M proteins have similar overall structure, 
with an HVR followed by a fibrinogen (Fg)- binding B 
repeat region and a carboxy- terminal part comprising C 
repeats and a wall- associated W region (Fig. 1A) (McMillan 
et al. 2013). The sequences of the B repeat regions of M1 
and M5 are as divergent as those of the HVRs, implying 
that M1 and M5 can be divided into a variable HVR- B 
part and a relatively conserved CW part (Fig. 1A). This 
observation, and evidence from the M5 system that each 
of the HVR and B regions contributes to virulence 
(Waldemarsson et al. 2009), suggested that both of these 
regions might escape Ab attack by similar mechanisms. 
We therefore hypothesized that weak immunogenicity char-
acterizes not only the HVR but also the B repeats, although 
it has been reported that the B repeats of an M protein 
are immunodominant (Fischetti and Windels 1988).
The studies of M1 and M5 described here show that 
both the HVR and the B repeat region indeed are weakly 
immunogenic, whereas the carboxy- terminal part is im-
munodominant. Thus, we identified a correlation between 
sequence variability and weak immunogenicity for M protein 
regions. A possible molecular explanation for the weak 
Figure 1. Schematic representations of the M1 and M5 proteins and analysis of cross- reactivity. (A) The M1 and M5 proteins have similar overall 
domain arrangement, with an amino- terminal HVR, a fibrinogen- binding B repeat region, a C repeat region and a wall- associated W region. Extensive 
sequence divergence characterizes not only the HVRs but also the B repeat regions, implying that M1 and M5 can be divided into a variable and a 
conserved part, as shown. Recombinant fragments of M1 and M5 used in this report are indicated. (B) Analysis showing virtual lack of cross- reactivity 
between the HVRs or between the B repeat regions, while the C repeat regions cross- react. Rabbit antisera, directed against the region in M1 or M5 
indicated at the top of each panel, were used to test reactivity with intact M1 or M5 immobilized in microtiter wells. For example, anti- (M1- HVR)/M5 
indicates the reactivity of anti- (M1- HVR) with immobilized intact M5. Because an antiserum raised against the C repeats of M1 was not available, 
analysis of cross- reactivity between the C repeats was only performed with anti- (M5- C). Bound rabbit Abs were detected with radiolabeled protein 
G. A low background binding observed with preimmune rabbit serum has been subtracted. Data in panel B show mean values ± SD and each analysis 
was performed three times.
(A)
(B)
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immunogenicity was provided by the demonstration that 
proteases selectively eliminated the HVR- B part from 
bacteria- bound M protein. On the basis of these data, we 
propose that the entire variable HVR- B part evades Ab 
attack not only through sequence variability, but also through 
weak immunogenicity resulting from protease attack.
Experimental Procedures
Bacterial strains and culture conditions
The reference S. pyogenes strains used here, the M1 strain 
SF370 (Ferretti et al. 2001) and the M5 strain Manfredo 
(Miller et al. 1988), were obtained from Dr M. Kehoe. 
The M1 strain 5448 and an SpeB- negative mutant of that 
strain (5448ΔspeB) were from Dr V. Nizet (Kansal et al. 
2003). The M1 strain MC25, which secretes an M1 protein 
lacking the most carboxy- terminal part, was from Dr M. 
Collin (Collin and Olsén 2000). Two M1 strains isolated 
from humans with invasive infections have been described 
(Lannergård et al. 2011). All S. pyogenes strains were grown 
without shaking in Todd- Hewitt broth supplemented with 
0.2% yeast extract (THY), in 5% CO2 at 37°C. Unless 
otherwise stated, the S. pyogenes cultures were supplemented 
with the cysteine protease inhibitor E64 (Sigma, St. Louis, 
Missouri, USA), used at 10 μmol/L, to prevent degrada-
tion of surface- localized M protein by any SpeB protease 
released from the bacteria (Elliott 1945; Aziz et al. 2004; 
Wei et al. 2005; Gustafsson et al. 2013). Cloning work 
employed Escherichia coli XL1 and DH5α, whereas protein 
production employed strain BL21. Strains of E. coli were 
grown with shaking in LB at 37°C and supplemented 
with ampicillin (100 μg mL−1) when appropriate.
Proteins
Recombinant M proteins and M protein fragments were 
purified as GST- tagged proteins, as described (Gustafsson 
et al. 2013). After removal of the GST moiety, these proteins 
included the amino- terminal sequence GPLGS, not present 
in the original protein. Intact M1 and M5, and HVR and 
BCW fragments derived from these proteins, have been de-
scribed (Lannergård et al. 2011; Gustafsson et al. 2013). For 
purification of the M1- (HVR- B), M1- CW, M5- B, and M5- CW 
fragments, the corresponding gene fragments were amplified 
as described (Gustafsson et al. 2013) from chromosomal 
DNA of strain SF370 or strain M5 Manfredo, with primers 
listed in Table S1, as follows: M1- (HVR- B): M1- F/M1B- 
dim- R2; M1- CW: M1C- F/M1- R; M5- B: M5B- F/M5B- dim- R; 
and M5- CW: M5C- F/M5- R. For isolation of the M1- (HVR- 
B- C) fragment, a supernatant of S. pyogenes strain MC25 
was subjected to affinity chromatography on Fg immobilized 
in a HiTrap column (GE Healthcare) (Collin and Olsén 
2000). Of note, the fragments M1- HVR, M1- (HVR- B), M5- 
HVR, and M5- B used here were dimerized by means of an 
added carboxy- terminal cysteine residue, not present in the 
native M protein, to enhance chances for coiled- coil forma-
tion and adoption of a native structure (Morfeldt et al. 2001; 
Sandin et al. 2002). The CW and BCW fragments were not 
dimerized by this procedure because the most carboxy- 
terminal part of an M protein does not form a coiled- coil 
(Nilson et al. 1995); however, the remaining part of these 
fragments is probably sufficient to promote coiled- coil for-
mation (Gubbe et al. 1997). The M1 and M5 fragments 
include the following amino acid residues of the mature M 
proteins: M1- HVR: 1–91; M1- (HVR- B): 1–158; M1- (HVR- 
B- C): 1–330; M1- BCW: 92–443; M1- CW: 154–443; M5- HVR: 
1–121; M5- B: 118–214; M5- BCW: 118–450; M5- CW: 209–
450. Protein Rib was isolated from Streptococcus agalactiae 
strain BM110, as described (Stålhammar- Carlemalm et al. 
1993; Larsson et al. 1996). Human Fg was from Enzyme 
Research Laboratories and protein G was from Sigma. Human 
elastase was from Elastin Products Company (Owensville, 
Missouri, USA) and streptococcal SpeB was from Toxin 
Technology (Sarasota, Florida, USA).
Animal and human antisera to M proteins
Rabbit antisera
Antisera to proteins or peptides were raised by s.c. im-
munization with 100 μg Ag in CFA, followed by two 
50 μg boosters in IFA. In the M1 system, anti- (M1- HVR) 
and anti- (M1- BCW) have been described (Lannergård 
et al. 2011). Anti- (M1- B) was raised by immunization 
with a synthetic 28- residue peptide, corresponding to the 
first B repeat and conjugated to the carrier OVA (Innovagen, 
Lund, Sweden). Anti- (M1- CW) was prepared by absorp-
tion of the anti- BCW serum on a HiTrap column con-
taining the immobilized M1- (HVR- B) fragment. In the 
M5 system, two different antisera against the M5- HVR 
were used in different experiments, as indicated. One of 
these sera was raised against a recombinant fragment de-
rived from the complete M5- HVR (Gustafsson et al. 2013); 
this antiserum was used for the cross- reactivity tests re-
ported in Figure 1B. The second anti- (M5- HVR) serum 
used here was raised against a synthetic peptide derived 
from residues 1–50 in the mature protein (Sandin et al. 
2006); this antiserum was used in the tests shown in 
Figures 5 and S2. The anti- (M5- B) and anti- (M5- C) sera, 
raised against peptides derived from the B and C regions, 
respectively, have been described (Sandin et al. 2006).
Mouse sera
Antisera to pure M proteins were recovered from mice 
(C3H/HeN) that had been immunized with 20 μg M1 
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or M5 mixed with alum, boosted with 10 μg protein 
after 4 weeks, and bled 2 weeks later (Lannergård et al. 
2011). Antisera from mice (C3H/HeN) infected with a 
sublethal dose of bacteria were recovered from animals 
infected i.p. 4 weeks earlier with 106 cfu of strain M5 
Manfredo (Lannergård et al. 2011) or with either of the 
M1 strains 5448 or 5448ΔspeB.
Human sera
The two human convalescent sera studied here were re-
covered from patients who had been hospitalized for 
invasive S. pyogenes M1 infection (Lannergård et al. 2011). 
Of note, these patients were treated with a combination 
of clindamycin and benzylpenicillin at admission. As re-
ported earlier, comparison of acute and convalescent sera 
demonstrated an increase in titer against M1, implying 
that the sera could be employed to analyze the human 
anti- M1 response during a single infection. Importantly, 
the corresponding M1 strains were available, allowing 
characterization of their M proteins.
Binding and inhibition assays with antisera
The assays analyzed the ability of Abs, elicited by M1 or 
M5, to react with recombinant fragments derived from 
these proteins, and with the intact M proteins. In all 
binding tests, maximal binding was defined as 100%. 
Because the M1 protein has a weak IgG- Fc- binding activ-
ity (Åkesson et al. 1994), unlike M5, appropriate controls 
were included, as indicated, to ensure that this property 
did not affect the results. However, in our experience 
Fc- binding has limited effects in studies with purified M1. 
Of note, the HVR fragments of M1 and M5 used here 
had been dimerized by means of carboxy- terminal cysteine 
residue, unlike the HVR fragments employed previously 
(Lannergård et al. 2011), possibly explaining why the anti- 
HVR reactivity of some sera was slightly higher than in 
the analysis reported previously.
Analysis of cross- reactivity between M1 and M5
Microtiter wells were coated overnight at 4°C by incuba-
tion with a solution (50 μL) of pure recombinant M1 or 
M5 (0.25 μg mL−1 in PBS), as indicated. All subsequent 
steps were performed at room temperature (Fig. 1B). After 
coating, the wells were blocked for 1 h with TBST- gel 
(Tris- buffered saline with 0.25% Tween- 20 and 0.25% 
gelatin). Rabbit antiserum (50 μL), diluted as indicated 
in TBST- gel, was then added and the wells were incu-
bated for 1 h. After washes with PBSAT (PBS with 0.02% 
NaN3 and 0.05% Tween- 20), radiolabeled protein G 
(~10,000 cpm in 50 μL TBST- gel) was added for detec-
tion of bound IgG, and after incubation for 1 h and new 
washes with PBSAT, the wells were cut out and bound 
protein G was determined in a γ- counter.
Direct binding of human and mouse Abs to M 
protein fragments
Microtiter wells were coated essentially as described above, 
using intact M protein and M protein fragments, as 
indicated (Fig. 2A, F, 3A, C and Fig. S2). The protein 
concentrations used (0.3 to 3.5 μg mL−1) had been op-
timized in preliminary experiments to give results allowing 
direct comparisons between data obtained for the dif-
ferent immobilized proteins (Lannergård et al. 2011). 
After blocking with TBST- gel, antisera were added at 
different dilutions, as indicated, followed by incubation 
for 1 h. Bound Abs were detected essentially as described 
above. For human sera, bound Abs were detected directly 
by incubation with radiolabeled protein G. For mouse 
sera, the wells were first incubated with goat anti- mouse 
Ig (Sigma, diluted 1000- fold) and then with protein G.
Inhibition assays with M protein fragments
Microtiter wells were coated by incubation with a solution 
(50 μL) of pure M1 (0.25–0.5 μg mL−1) (Fig. 2C, E and 
4B). Human convalescent anti- M1 serum, diluted 300- or 
600- fold, was preincubated for 30 min with the protein 
being tested for inhibitory ability, in a volume of 100 μL. 
The samples were then analyzed for remaining Ab- binding 
activity, as described for direct binding tests. Of note, 
the Abs in a human control serum showed negligible 
binding under these conditions, demonstrating that the 
weak Fc- binding activity of M1 did not influence the 
result.
Effect of Fg on Ab- binding
Microtiter wells were coated overnight with a solution (50 μL) 
of pure recombinant M1 (1.0 μg mL−1), followed by the 
addition of Fg, as indicated, in a volume of 50 μL and 
incubation for 1 h at room temperature (Fig. 4A). Human 
convalescent anti- M1 serum, diluted 3000- fold, was then 
added in a volume of 50 μL, and Ab- binding was deter-
mined, as described above. Serum from a nonimmune hu-
man donor showed low binding to M1 under these conditions, 
demonstrating that Fc- binding did not affect the results.
Phagocytosis assays
The assay, based on the classical Todd- Lancefield test 
(Lancefield 1957), employed freshly drawn nonimmune 
778 © 2015 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd. 
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Figure 2. The entire HVR- B part of M1 is weakly immunogenic. (A) Analysis of convalescent sera from two patients, who were known to have 
responded to M1 during Streptococcus pyogenes infection. Each panel shows data obtained with one patient serum, as indicated. The human sera 
were tested for reactivity with the pure proteins indicated, immobilized in microtiter wells. Bound human Abs were detected with radiolabeled protein 
G. The assays had been optimized to allow direct comparisons between the curves. Of note, the Fc- binding ability of M1 was negligible under the 
conditions used here and did not influence the results. (B) Western blot analysis with the human convalescent sera and M1 fragments, as indicated. 
The analysis was performed under nonreducing conditions, because the HVR and HVR- B fragments had been dimerized via a carboxy- terminal 
cysteine residue, not present in the native M1 protein, to promote coiled- coil formation. This is reflected in the molecular masses observed. For 
unknown reasons, the dimerization of the HVR- B fragment was incomplete. Data are representative of two independent experiments. (C) Inhibition 
test with one of the human anti- M1 sera and M1 fragments. Reactivity of the human Abs with intact M1 immobilized in microtiter wells was inhibited 
with the fragments indicated. Similar data were obtained with the second human anti- M1 serum. (D) Opsonization- phagocytosis assay with whole 
human blood and the two human convalescent anti- M1 sera. Serum from a nonimmune human donor was used as a negative control and rabbit 
anti- (M1- HVR) was used to demonstrate that the system allowed opsonization. The figure shows average results based on two separate experiments, 
both of which yielded very similar results. MF, multiplication factor. (E) Inhibition test with intact M1 and its HVR- B- C fragment, which lacks most of 
the W region. The test system was the same as in panel C. An unrelated protein, streptococcal protein Rib, was used as negative control. The panel 
shows results obtained with one human serum; similar data were obtained with the second human serum. Controls with nonimmune human serum 
showed that Fc- binding was negligible in the tests shown in panels C and E. (F) Abs from mice (n = 9) immunized with pure M1 were tested for 
reactivity with proteins immobilized in microtiter wells, as indicated. Bound mouse Abs were detected by incubation with goat anti- (mouse Ig), and 
bound goat IgG was subsequently identified by incubation with radiolabeled protein G. No binding was observed with preimmune mouse serum, 
confirming that Fc- binding did not affect the results. (G) Western blot analysis with two of the mouse anti- M1 sera. Bound mouse Abs were detected 
as in F. Data are representative of two independent experiments. Data in panels A, C, E, and F show mean values ± SD and each analysis was 
performed three times.
(A)
(C) (D) (E)
(G)(F)
(B)
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human blood, that is blood allowing rapid growth of the 
strain used. Hirudin was used as anticoagulant (Thern 
et al. 1998). The assay employed a small inoculum (200–
400 cfu) of log- phase bacteria, grown in THY without 
E64, and diluted in the same medium. The inoculum 
(25 μL) was incubated for 10 min with 25 μL test serum 
and 25 μL of normal rabbit serum. Human blood (285 μL) 
was then added. After rotation at 37°C for 3 h, each sample 
Figure 3. Also in the M5 protein the entire HVR- B part is weakly immunogenic. (A) Abs from mice (n = 8) infected with a sublethal dose of M5 bacteria 
were tested for reactivity with pure proteins immobilized in microtiter wells, as indicated. Bound mouse Abs were detected by incubation with rabbit 
anti- (mouse Ig), followed by protein G. Preimmune mouse serum lacked reactivity, reflecting the lack of Fc- reactivity of M5. (B) Western blot analysis 
with two of the sera from infected mice. Note that the HVR and B fragments had been dimerized via a carboxy- terminal cysteine residue, not present 
in the native M5 protein, to promote coiled- coil formation. The analysis was therefore performed under nonreducing conditions. The M5- HVR fragment 
migrated aberrantly, as previously observed for some dimerized HVRs (Morfeldt et al. 2001). Bound Abs were detected as in panel A. (C and D) Analysis 
of Abs from mice (n = 7) immunized with pure M5. The procedures used were similar to those in panels A and B. Data in panels A and C show mean 
values ± SD and each analysis was performed three times. The blotting data in panels B and D are representative of two independent experiments.
(A)
(C) (D)
(B)
Figure 4. The weak antibody response does not reflect lack of antibody detection. (A) Search for possible ligand- induced binding sites (LIBS). Human 
convalescent anti- M1 serum was used to detect pure M1 immobilized in microtiter wells, and the effect of fibrinogen (Fg) on binding was determined. 
Data obtained with the two human sera are shown. (B) Search for possible modification affecting antigenicity. Human anti- M1 Abs, present in the 
serum of a convalescent patient, were used to detect immobilized M1, in this case the M1- (HVR- B- C) fragment isolated directly from Streptococcus 
pyogenes. Binding was inhibited with the same M1 preparation (“streptococcus M1”) and with recombinant M1 produced in E. coli. Streptococcal 
protein Rib, which is unrelated to M proteins, was used as negative control. Similar data were obtained with the second human convalescent serum. 
For panels A and B, controls with nonimmune human serum showed that Fc- binding did not affect the results. Data show mean values ± SD; each 
analysis was performed three times.
(A) (B)
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was plated on blood agar plates to determine bacterial 
concentration, and the multiplication factor (MF) was 
calculated. The normal rabbit serum was included because 
preliminary experiments indicated that it enhanced bacterial 
growth in the system. The positive control was a previ-
ously described rabbit anti- (M1- HVR) serum (Lannergård 
et al. 2011) and the negative control was serum from a 
human lacking opsonizing anti- M1 Abs. The two patient 
sera tested for opsonizing activity had been dialyzed against 
PBS, to remove any remaining  antibiotics, and the two 
control sera were treated similarly.
Protease digestions with bacteria
The analysis employed strain SF370 (M1) or strain 
Manfredo (M5), as indicated, and an assay in which spe-
cific rabbit Abs were used to detect loss of an M protein 
region after protease digestion. Bacteria grown overnight 
in THY supplemented with E64 were washed 3 times in 
PBS and suspended to OD620 = 4. A sample (500 μL) 
of the bacterial suspension was mixed with an equal vol-
ume of PBS containing elastase or SpeB, to obtain the 
final enzyme concentration indicated. For digests with 
SpeB, 10 mmol/L DTT was included, to promote activa-
tion of the enzyme. After incubation at 37°C for 1 h, 
the samples were chilled on ice and protease inhibitor 
was added to a final concentration of 1 mmol/L for the 
elastase- inhibitor AEBSF (Sigma) and 10 μmol/L for the 
SpeB- inhibitor E64. All following steps were performed 
at room temperature. The bacteria were washed three 
times in PBSAT and serial dilutions were prepared, as 
indicated, in a suspension of E. coli, included to allow 
formation of a pellet after centrifugation. For analysis of 
remaining Ab- binding activity, a sample (90 μL) of each 
bacterial dilution was mixed with a fixed amount (10 μL) 
of the rabbit antiserum indicated, or with preimmune 
rabbit serum, used as control. The final dilution of rabbit 
antiserum used was based on preliminary optimization 
tests and was 300- to 1600- fold for the different sera. To 
simplify comparisons between results obtained with the 
three different antisera used, their concentrations were 
adjusted to yield similar results with undigested bacteria, 
as determined in preliminary tests (Fig. 5, left panels). 
After incubation for 1 h with antiserum, the bacteria were 
washed twice with PBSAT, resuspended in PBSAT (100 μL) 
containing ~10,000 cpm radiolabeled protein G, and in-
cubated for 1 h. The bacteria were then washed once 
with PBSAT and radioactivity in the pellets was determined 
in a γ- counter. Binding is presented as a percentage of 
the maximal binding obtained for each antiserum used. 
As the results are presented here, loss of an M protein 
region is reflected in a left- shift of the corresponding 
Ab- binding curve (Fig. 5).
Other methods
Radiolabeling of protein G with 125I, SDS- PAGE under 
reducing or nonreducing conditions, and Western blots 
were performed essentially as described (Stålhammar- 
Carlemalm et al. 1993; Lannergård et al. 2011). Protein 
sequence alignments were performed with the ClustalW 
program (http://www.ebi.ac.uk/Tools/msa/clustalw2/). For 
analysis of Fg- binding to M proteins and M protein frag-
ments (Fig. S1), equimolar amounts of the bacterial pro-
teins were used to coat microtiter wells, followed by 
incubation with Fg at the concentration indicated and 
detection of bound Fg with rabbit anti- Fg (Dako) and 
radiolabeled protein G.
Ethics statement
Animal experiments were performed with permission from 
the Animal Experimental Ethics Committee at Lund District 
Court. Experimental infections were performed in a level 
P2 biohazard laboratory within the animal facility of the 
Department of Laboratory Medicine, Lund University. The 
serum samples from humans with invasive M1 infection 
were obtained with approval from the Research ethics 
committee at Karolinska Institutet and with written in-
formed consent from the subjects or their legal guardians. 
Phagocytosis tests were performed with blood samples 
obtained from human volunteers, with permission from 
the Ethical Review Board of the Medical Faculty, Lund 
University and with written informed consent from the 
donors.
Results
Experimental system: the M1 and M5 
proteins
Our work employed the intact M1 and M5 proteins and 
fragments derived from these proteins (Fig. 1A). 
Comparative studies of these two clinically important M 
proteins were of interest because their HVRs and B repeat 
regions exhibit extreme sequence divergence and show 
little or no antigenic cross- reactivity (Fig. 1A and B).
The entire variable HVR- B part of M1 is 
weakly immunogenic in humans and mice
Previous analysis of the human Ab response to M1 in-
dicated that most Abs were directed against a fragment 
designated BCW (comprising the B and C repeats and 
the W region), whereas the HVR elicited a weak response 
(Lannergård et al. 2011). This analysis was performed 
with sera obtained from two patients, for which both 
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Figure 5. The variable part of bacteria- bound M1 or M5 is selectively eliminated by proteases. (A, B) M1- expressing Streptococcus pyogenes bacteria 
were either untreated (control) or treated with elastase or SpeB at the concentrations indicated. Different bacterial dilutions were subsequently tested 
for reactivity with a fixed amount of rabbit antiserum specific for the M1 region indicated. In this test, loss of an M protein region was seen as a 
reduction in binding of the corresponding rabbit Abs, resulting in a left- shift of the binding curve. To simplify comparisons, the three rabbit antisera 
had been adjusted to have similar reactivity with untreated bacteria (left panels). Binding of rabbit Abs was detected with radiolabeled protein G. As 
shown, preimmune rabbit serum showed little reactivity, demonstrating that IgG- Fc- binding to M1 was negligible in this test. (C, D) Treatment of 
M5- expressing S. pyogenes with elastase or SpeB. The analysis was performed as for panels A and B, employing rabbit antisera specific for the M5 
regions indicated. Data show mean values ± SD; each analysis was performed three times.
(A)
(B)
(C)
(D)
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acute and convalescent serum and the infecting M1 strain 
were available, allowing the demonstration that the two 
patients had responded to the corresponding M1 protein 
during the recent infection. Further tests showed that 
the Abs in these human sera reacted equally well with 
intact M1 and its CW fragment but hardly at all with the 
HVR or HVR- B fragments, as judged by tests with pro-
teins immobilized in microtiter wells (Fig. 2A). Thus, 
the analysis indicated that not only the HVR, but the 
entire HVR- B part, was weakly immunogenic during hu-
man infection. Several lines of evidence supported this 
conclusion. First, the selective reactivity with intact M1 
and the CW fragment could not be explained by the 
IgG- Fc- binding ability of M1 (Åkesson et al. 1994) because 
controls showed that <7% of the binding was caused by 
Fc- reactivity (data not shown). Second, only intact M1 
and the CW fragment were detected in western blot 
analysis with the human convalescent sera, and no signal 
was obtained with a human control serum, confirming 
that the reactivity did not reflect IgG- Fc- binding (Fig. 2B). 
Third, binding of the human Abs to M1 could be com-
pletely inhibited by intact M1 and the CW fragment, but 
not by the HVR or HVR- B fragment (Fig. 2C). Fourth, 
the lack of reactivity with the HVR- B fragment did not 
reflect denaturation because this fragment and intact M1 
had similar Fg- binding properties (Fig. S1A). Fifth, the 
lack of reactivity with the immobilized HVR and HVR- B 
fragments did not reflect a general inability to detect Abs 
to these fragments, as shown by controls [see (Lannergård 
et al. 2011) and Experimental Procedures]. Finally, the 
lack of detection of Abs to the HVR- B part did not 
reflect sequence variability in M1, as shown by analysis 
of DNA from the patient strains. This analysis showed 
that the patient strains and the reference strain expressed 
M1 proteins in which the HVR and B regions were iden-
tical, except for a single HVR residue that does not affect 
Ab recognition (Lannergård et al. 2011). Thus, a variety 
of analyses supported the conclusion that the human 
anti- M1 Abs were directed mainly against the conserved 
CW part. As discussed below, it is unlikely that the strik-
ing immunodominance of the conserved part can be 
explained as a recall response, reflecting previous S. pyo-
genes infection.
The HVR of an M protein is the major target for 
opsonizing Abs (Jones and Fischetti 1988; Fischetti 1989; 
Sandin et al. 2006), as determined in the whole blood 
assay commonly employed for S. pyogenes work (Lancefield 
1957). The virtual absence of anti- HVR Abs in the two 
human sera therefore suggested that they would not pro-
mote phagocytosis in this assay. Both sera indeed lacked 
opsonizing capacity, while a hyperimmune rabbit anti- HVR 
serum promoted efficient killing, as expected (Fig. 2D). 
Thus, both immunochemical and functional tests indicated 
that anti- HVR Abs were largely absent from the human 
M1 sera.
The W region of bacteria- bound M1 is probably hidden 
in the cell wall (Fischetti 1989), suggesting that anti- M1 
Abs, elicited during an infection and detected with the 
CW fragment, might be directed mainly against the C 
repeat region. On the other hand, it seemed possible that 
some virtually intact M1 would be released from the 
bacteria, as described for protein A of Staphylococcus aureus 
(Becker et al. 2014), favoring the formation of Abs to 
the W region. However, binding of human anti- M1 Abs 
to M1 was inhibited not only by intact M1, but also by 
a truncated M1 protein lacking most of the W region 
(Fig. 2E), indicating that the majority of the human anti-
 M1 Abs were directed against the C repeat region. For 
unknown reasons, the truncated M1 inhibited less efficiently 
than intact M1, but both proteins caused essentially com-
plete inhibition, indicating that they contained the same 
epitopes.
The Ab response to pure M1 protein was analyzed in 
immunized mice. The Abs elicited in these mice reacted 
equally well with intact M1 and the CW fragment, but 
had low reactivity with the HVR and HVR- B fragments 
(Fig. 2F), indicating that the entire variable part was weakly 
immunogenic also after immunization with pure protein. 
The binding to fragments derived from the variable part 
was somewhat higher for the mouse sera than for the 
human sera, but binding to the HVR was >50- fold lower 
and binding to the HVR- B fragment was at least 10- fold 
lower than to intact M1. No reactivity was seen in tests 
with preimmune mouse serum, confirming that the bind-
ing did not represent Fc- reactivity (not shown). Western 
blot analysis with two of the nine mouse sera supported 
the conclusion that the Ab response was largely directed 
against the conserved part of M1 (Fig. 2G). Thus, the 
entire variable part of M1 was weakly immunogenic not 
only during human infection but also in immunized mice.
The entire HVR- B part is weakly 
immunogenic also in the M5 protein
The Ab response to different regions in the M5 protein 
during infection was analyzed for mice infected with a 
sublethal dose of M5- expressing S. pyogenes. The anti- M5 
Abs elicited in these infected mice reacted equally well 
with the CW fragment and intact M5 but had 15- 40- fold 
lower reactivity with the HVR and the B fragment, as 
judged by tests with immobilized proteins (Fig. 3A). The 
immunodominance of the conserved part was less dramatic 
in this system than in M1- infected humans (Fig. 2A), 
but the overall picture was similar in the two systems. 
Thus, the analysis indicated that the entire variable HVR- B 
part of M5 is weakly immunogenic in infected mice. 
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Western blot analysis with two of the eight mouse sera 
supported this conclusion (Fig. 3B). Of note, the weak 
reactivity with the HVR and B fragments could not be 
explained by denaturation because the HVR retained abil-
ity to bind human factor H (Gustafsson et al. 2013), and 
the B fragment retained ability to bind Fg, although with 
reduced apparent affinity for Fg (Fig. S1B). As described 
for the M1 system, the weak response to the HVR and 
B regions did not reflect inability to detect Abs to these 
regions because the system had been optimized to allow 
detection of Abs against different M5 regions with the 
same sensitivity. Finally, the selective reactivity with intact 
M5 and the CW fragment did not reflect Fc- reactivity, 
because M5 lacks IgG- Fc- binding ability (Kehoe 1994).
The Ab response to pure M5 protein was analyzed in 
mice immunized with recombinant M5. The antisera re-
acted equally well with intact M5 and the CW fragment, 
but the reactivity with the HVR and the B fragment was 
~100- fold lower, according to tests with immobilized 
proteins (Fig. 3C). In agreement with this result, western 
blot analysis with two of the seven mouse antisera showed 
lack of signal for the HVR and B fragments (Fig. 3D). 
Thus, the entire variable HVR- B part of M5 was weakly 
immunogenic not only during infection but also after 
immunization with pure protein.
Are antibodies to the variable part present 
but not detected?
An antigen that elicits a weak Ab response, as determined 
by standard methods, is by definition weakly immunogenic 
with regard to the humoral response. However, apparent 
lack of Abs could conceivably reflect lack of Ab detection 
rather than absence of Abs. In the M protein system 
studied here, this hypothesis would imply that the vari-
able HVR- B part elicits Abs that largely go undetected 
in standard assays. We considered two hypothetical sce-
narios that could result in lack of Ab detection.
In one scenario, Abs to the variable part are directed 
mainly against epitopes that appear after the binding of 
a host ligand, resulting in apparent lack of Abs when 
analysis is performed in the absence of the ligand. Studies 
with certain monoclonal Abs have allowed the identifica-
tion of such ligand- induced binding sites (LIBS) in ligand- 
receptor systems (Frelinger et al. 1990; Speziale et al. 
1996), but we are not aware of any system where lack 
of ligand- binding can explain why a polyclonal Ab re-
sponse appears to be weak. This problem was nevertheless 
studied in the M1 system, focusing on the Fg- binding B 
repeat region. Specifically, we analyzed whether human 
anti- M1 sera showed increased reactivity with pure M1 
when Fg was added. In this analysis, Fg did not stimulate 
binding but caused a slight inhibition of binding for each 
of the two patient sera (Fig. 4A). Similar results were 
obtained in the M5 system, with sera obtained from mice 
immunized with pure M5 (data not shown). Thus, analysis 
in the M1 and M5 systems did not support the hypothesis 
that Abs to the variable part went undetected because 
the analysis was performed in the absence of ligand.
In another possible scenario, Abs to the variable part 
were not detected, because this part is only immunogenic 
after having been structurally modified, which might occur 
in streptococci. Accordingly, Abs against the modified 
variable part would not have been detected, because re-
combinant unmodified protein was used in immunochemi-
cal tests. Moreover, the hypothesis predicts that the 
unmodified variable part present in recombinant protein 
would not elicit Abs. Such a remarkable situation was 
recently described for a group of Staphylococcus aureus 
proteins (Hazenbos et al. 2013). To analyze whether M 
protein has similar properties, we employed the human 
Abs described above to detect immobilized M1 protein 
isolated directly from S. pyogenes. If a considerable frac-
tion of the human Abs detect a modified form of M1, 
it should be possible to efficiently inhibit this binding 
with M1 protein isolated directly from streptococci, but 
not with recombinant M1. However, M1 preparations of 
both types caused virtually complete inhibition (Fig. 4B). 
Thus, the analysis did not provide support for the hy-
pothesis that lack of Ab detection reflects structural 
modification.
The variable part of bacteria- bound M 
protein is selectively eliminated by 
proteases
We hypothesized that the weak immunogenicity of the 
variable part in M1 and M5 resulted from sensitivity to 
proteases. In this scenario, the variable part plays a key 
role in pathogenesis but is also rapidly eliminated by pro-
tease attack, resulting in a limited Ab response and immune 
escape. To analyze this hypothesis, we employed human 
elastase, the potent serine protease of neutrophils (Pham 
2006), and SpeB, the well- known cysteine protease of S. pyo-
genes (Nelson et al. 2011). Elastase was studied because it 
is a major protease in inflamed tissue, whereas SpeB was 
studied because it is secreted from S. pyogenes and may 
attack surface proteins on the same bacteria, in particular 
M protein (Elliott 1945; Berge and Björck 1995; Wei et al. 
2005). Attack by SpeB cannot affect the Ab response when 
pure M protein is used for immunization, but this enzyme 
was nevertheless studied, because it could affect the response 
during an infection, when large amounts of SpeB might 
be present in the bacterial microenvironment.
Our analysis was initially focused on pure M proteins. 
In such analysis, incubation of pure M proteins with 
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proteases at 37° did not allow demonstration of selective 
sensitivity of the variable part. This result was not un-
expected because the two- coiled coil chains of pure M 
protein are known to dissociate at 37°, probably resulting 
in loss of secondary and tertiary structure (Åkerström 
et al. 1992; Cedervall et al. 1995; Nilson et al. 1995). In 
an attempt to circumvent this problem, incubations were 
performed at 25°, but again with inconclusive results, 
possibly due to the unphysiological conditions used. These 
results suggested that analysis should be performed under 
conditions more similar to those encountered in vivo and 
focused interest on the ability of bound plasma proteins 
to stabilize the dimeric form of M proteins at 37° (Cedervall 
et al. 1995; Nilson et al. 1995). However, protease diges-
tion in the presence of plasma was not attempted, because 
an Fg- binding M protein will form precipitates with the 
Fg present in plasma (Kantor 1965). This situation 
prompted us to perform further work with whole bacteria, 
in which covalent binding of M protein to the cell wall 
(Schneewind and Missiakas 2012) likely limits chain dis-
sociation (Cedervall et al. 1995).
Bacteria were cultivated in broth supplemented with 
the cysteine protease inhibitor E64, to avoid possible deg-
radation of M protein by SpeB secreted into the culture 
(Elliott 1945; Aziz et al. 2004; Wei et al. 2005; Gustafsson 
et al. 2013). Washed bacteria were subsequently treated 
with pure elastase or SpeB, and loss of an M protein 
region was determined as loss of reactivity with rabbit 
Abs against the corresponding region (Fig. 5). Of note, 
the rabbit Abs used for this analysis had been shown to 
be specific for the corresponding region of the M protein 
studied (Fig. S2). As presented here, loss of an M protein 
region after protease treatment is reflected in a left- shift 
of the corresponding Ab- binding curve. For each enzyme, 
we employed two different concentrations, chosen on the 
basis of preliminary experiments.
For M1- expressing bacteria, the different rabbit antisera 
had been adjusted to have the same reactivity with un-
treated control bacteria, to simplify comparisons (Fig. 5A 
and B, left panels). After enzyme treatment, a different 
picture emerged. In tests with elastase, treatment with 
50 nmol/L enzyme caused a strong loss in reactivity with 
anti- HVR and anti- B (Fig. 5A, middle panel), and treat-
ment with 100 nmol/L enzyme caused almost complete 
loss of reactivity with these two antisera (Fig. 5A, right 
panel). In contrast, reactivity with anti- CW was virtually 
unchanged after enzyme treatment. Of note, preimmune 
rabbit serum had negligible binding activity in this assay, 
demonstrating that the weak Fc- binding ability of M1 
did not influence the results. Similar results were obtained 
with SpeB tested at two concentrations (Fig. 5B). Thus, 
the entire variable HVR- B part of bacteria- bound M1 
was selectively eliminated by treatment with elastase or 
SpeB, whereas the conserved part remained largely 
unaffected.
The data on SpeB suggested that attack by this protease 
might affect the Ab response to M1 during an infection. 
To analyze this hypothesis, we infected two groups of 
mice with sublethal doses of the M1 strain 5448 and an 
SpeB- negative mutant of that strain, respectively. Only 
some of the infected mice responded to M1, but analysis 
of two sera from each group indicated that the Ab re-
sponse to the variable part was similar for all mice ana-
lyzed, that is it was weak also in the absence of SpeB 
(Fig. S3). Thus, attack by SpeB alone is not sufficient to 
explain the weak Ab response to the variable part of M1 
during experimental infection.
In the M5 system, the effects of proteases on bacteria- 
bound protein were similar but not identical to those 
obtained in the M1 system. In tests with elastase, the 
HVR was largely lost by enzyme treatment, whereas the 
conserved part was unaffected but the B region showed 
intermediate sensitivity (Fig. 5C). Similar results were 
obtained with SpeB (Fig. 5D). Thus, a gradient of protease 
sensitivity could be discerned in the M5 system, but the 
overall picture was very similar to that observed in the 
M1 system.
Discussion
The data described here and in an earlier report (Lannergård 
et al. 2011) challenge the common assumption that a 
highly variable region in a microbial virulence factor elicits 
a stronger Ab response than other parts of the protein. 
On the contrary, our data support the paradoxical hy-
pothesis that some variable regions are weakly immuno-
genic, because they are so important for virulence, that 
evolution has favored the appearance of at least two 
mechanisms that limit Ab attack on these regions, sequence 
variability and weak immunogenicity.
Our work employed the streptococcal M1 and M5 
proteins, which have similar overall structure, with HVR, 
B, C, and W regions. In previous studies of these M 
proteins, we compared the Ab responses to the HVR and 
the remaining part of the M protein (designated BCW) 
and found that that the HVR elicited a weak Ab response, 
whereas the BCW part was immunodominant (Lannergård 
et al. 2011). Thus, our data supported the hypothesis that 
a highly variable region may escape Abs by being weakly 
immunogenic. However, the situation has remained unclear 
for the B repeat region. The extensive sequence divergence 
in this Fg- binding region suggested to us that it is subject 
to immune pressure and might have the same immuno-
logical properties as the HVR. In agreement with this 
hypothesis, we found that the B repeats of M1 and M5 
indeed elicited a weak Ab response. In contrast, it has 
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been proposed that the B repeat region is immunodomi-
nant in the M6 protein (Fischetti and Windels 1988), for 
which the B repeats are virtually identical to those in 
M5 (Miller et al. 1988). However, the conclusions of the 
M6 study were mainly based on work with short synthetic 
peptides, which may have aberrant immunological proper-
ties, and tests with larger fragments reported in that study 
do not disagree with the conclusion that the B region is 
weakly immunogenic also in M6. A coherent picture is 
therefore emerging, indicating that the entire variable part 
of an M protein elicits a weak Ab response.
The antisera studied here were obtained from patients 
and from infected mice, and from mice immunized with 
pure M1 or M5. In all cases, the results supported the 
conclusion that not only the HVR but also the B repeat 
region was weakly immunogenic, whereas the conserved 
part was immunodominant. For the human sera, it is 
possible that a recall response contributed to the result, 
reflecting previous S. pyogenes infection(s), but a recall 
response cannot explain the results obtained with mice. 
Moreover, there was virtually no response to the variable 
HVR- B part of M1 in the convalescent sera studied here, 
favoring the notion that this part is weakly immunogenic 
in humans. The inability of the human sera to promote 
phagocytosis supports the conclusion that they had low 
levels of anti- HVR Abs. This finding agrees well with 
early reports that type- specific opsonizing Abs appear only 
after prolonged S. pyogenes infection (Denny et al. 1957; 
Lancefield 1959) and are not found in patients treated 
with penicillin (Daikos and Weinstein 1951; Denny et al. 
1957; Siegel et al. 1961). Importantly, the weak Ab re-
sponse to the variable part of an M protein may limit 
the development of herd immunity, possibly allowing 
reinfection with strains of the same M type.
Several explanations may be envisaged for the weak 
immunogenicity of the variable part of an M protein, 
including lack of defined structure (Dey et al. 2009), se-
lective elimination by proteases, and limited affinity matu-
ration of the corresponding B cells (Pauli et al. 2014). 
Among these alternatives, our interest was focused on 
protease sensitivity, a property traditionally attributed to 
the type- specific part of an M protein (Lancefield 1943). 
It was not technically possible to perform studies with 
pure M proteins, but in tests with intact bacteria we found 
that the variable part of M protein indeed was selectively 
eliminated by digestion with elastase or SpeB, while the 
conserved part was resistant. This finding supports the 
hypothesis that weak immunogenicity is a result of protease 
attack and provides a possible explanation for the surpris-
ing fact that M protein is sensitive to proteases, unlike 
many other bacterial surface proteins. Indeed, protease 
sensitivity of the variable part may be an essential feature 
of M protein, allowing it to evade host immunity.
Host proteases that might attack M protein during 
S. pyogenes infection include elastase and other neutrophil 
proteases, and plasminogen activated by bacterial strep-
tokinase (Sun et al. 2004). Our studies indicated that 
attack by streptococcal SpeB is not sufficient to explain 
the weak immunogenicity of the variable part during in-
fection, but this result does not exclude that SpeB is one 
of several proteases that attack M protein in this setting. 
Molecular features that might favor attack on the variable 
part include local irregularities in the coiled- coil (Nilson 
et al. 1995; McNamara et al. 2008), the wall- distal loca-
tion of the variable part, and protection of the conserved 
part by bound albumin (Åkesson et al. 1994; Retnoningrum 
and Cleary 1994; Sandin et al. 2006). The fate of the 
variable region after protease attack is not known, but a 
well- defined fragment, similar to the pepM fragment re-
leased after treatment of S. pyogenes with pepsin under 
suboptimal conditions (Beachey et al. 1977), was not 
identified in our digests (data not shown). This result 
does not exclude that M protein fragments might be lib-
erated in vivo and could have important biologic effects, 
even if they are not immunogenic (Herwald et al. 2004; 
Schmitt et al. 2010).
Formal proof that the weak immunogenicity of the 
variable part reflects protease sensitivity may require the 
demonstration that a mutant M protein, which lacks pro-
tease sensitive sites, elicits a good Ab response to the 
variable region. It remains uncertain whether such a mutant 
protein can be constructed and preliminary attempts to 
identify a protease sensitive site were unsuccessful. 
Nevertheless, our findings demonstrate an intriguing cor-
relation between weak immunogenicity and proteolytic 
elimination, supporting the notion that these properties 
are functionally related.
Any mechanism that allows S. pyogenes to evade Ab 
attack has most likely evolved at mucosal sites and other 
epithelial surfaces, where immune escape provides a selec-
tive advantage by enhancing chances for transmission to 
a new host (Anderson and May 1986). To explain the 
data reported here, we therefore propose that the variable 
HVR and B regions of M1 and M5 have key functions 
during the establishment of infections at epithelial surfaces 
and are subjected to immune pressure in that setting, 
but also are rapidly eliminated through proteolytic attack 
and therefore are weakly immunogenic. Accordingly, it 
would be of particular interest to analyze the Ab response 
to M protein in mucosal and other epithelial microen-
vironments, but such analysis is not yet feasible. Our 
study was therefore based on studies of serum Abs, which 
may be used to evaluate local immunity, because several 
lines of evidence indicate that induction of mucosal im-
munity results in serum IgG responses (Lee et al. 2003; 
Takahashi et al. 2009). Similarly, serum IgG induced by 
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parenteral vaccination confers protection at mucosal sur-
faces, a prerequisite for the success of many vaccines 
(Robbins et al. 1995; Brandtzaeg 2007). Thus, the intimate 
connection between mucosal and systemic immunity al-
lows studies of serum Abs to be used as a surrogate for 
the analysis of locally produced Abs. Of note, studies of 
serum Abs are also highly relevant for understanding of 
the response to vaccinations.
The hypothesis, that the HVR and B regions play key 
roles at epithelial surfaces, does not exclude that they 
also promote virulence during invasive infection 
(Waldemarsson et al. 2009) but focuses interest on the 
possible role of these regions at epithelia. The function 
of the HVRs in M1 and M5 remains unclear, but they 
might promote adhesion to epithelial cells (Wang and 
Stinson 1994; Penfound et al. 2010), a key step in 
pathogenesis that should be highly vulnerable to Ab 
attack. If the HVR promotes adhesion, an additional 
role for protease attack could be to promote bacterial 
dispersal in the infected tissue (Connolly et al. 2011). 
In the M5 system, the ability of the HVR to bind  human 
factor H may contribute to virulence, but the role of 
factor H in S. pyogenes infection remains unclear 
(Gustafsson et al. 2013). For the B repeat region, the 
main function is probably to inhibit phagocytosis 
(Carlsson et al. 2005), a function that may be of major 
importance during the establishment of an infection at 
an epithelial surface, although phagocytosis resistance 
commonly is analyzed in a whole blood assay (Lancefield 
1957). Accordingly, the B repeat region could be an 
important target for protective Abs at epithelia. In blood, 
Fg apparently competes with Abs for binding to the B 
repeats (Sandin et al. 2006), but the low concentration 
of Fg in secretions such as saliva should limit the 
 opportunity for competition at epithelial surfaces 
(Berckmans et al. 2011).
In summary, our studies of the M1 and M5 proteins 
indicate that each of the highly variable HVR and B repeat 
regions elicits a weak Ab response, a property that might 
be explained by protease attack. These findings support 
the notion that the entire variable HVR- B part evades 
Abs not only by sequence variability but also by weak 
immunogenicity, and they focus interest on weak im-
munogenicity as an immune escape mechanism that po-
tentially is of general importance.
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Figure S1. Binding of fibrinogen to the HVR- B fragment 
of M1 and the B fragment of M5.
Figure S2. Specificity of rabbit antisera used to detect 
different regions in M1 and M5.
Figure S3. Absence of SpeB does not affect the Ab  response 
to M1 during experimental infection.
Table S1. Primers used for PCR amplification.
